Ymir Genomics and the Knight Cancer Institute at Portland-based Oregon Health & Science University are joining forces to develop urinary biomarkers that will be able to detect hepatocellular carcinoma in at-risk patients.
Under the agreement, which is supported by OHSU Proteomics Shared Resource, the institute will tap Ymir's proprietary urinary extracellular vesicle technology. Ymir's technology isolates extracellular vesicles and analyzes miRNA profiles of urine samples from liver cancer patients and high-risk cirrhotic patients. OHSU will then study the same vesicles and determine protein profiles.
"It's exciting to be collaborating with the team at Ymir on this project. This is a wonderful example of what can be accomplished when bringing basic scientists, clinicians and industry together," said Larry David, PhD, director of the OHSU Proteomics Shared Resource. "The work dovetails quite well with the major research goal of the Knight Cancer Institute, which is to be able to detect cancers earlier so they can be more effectively treated."
More articles on data analytics & precision medicine:
Geisinger launches national precision medicine initiative, appoints Huntington Willard director
AMA CEO outlines opportunities for health data
NantHealth's genetic cancer tests revenue exceeds $1M in Q3: 4 things to know